Leerink Partnrs Has Positive Forecast for REGN Q1 Earnings
Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...
Leerink Partners Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Outperform
Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...
Regeneron upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...
Fintel on MSN5d
Leerink Partners Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...
Nasdaq6d
Leerink Partners Upgrades Regeneron Pharmaceuticals (LSE:0R2M)
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...
AMD, Spotify downgraded: Wall Street's top analyst calls
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...